

11/10/00  
JC813 U.S. PTO

11-13-00

A

Attorney Docket No.: 5563.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

Express Mail Label No. EL285641612US  
Date of Deposit: November 10, 2000

JC825 U.S. PTO  
09/710760  
11/10/00

Sir:

This is a request for filing a **Divisional** application under 37 C.F.R.  
1.53(b) of

**Applicant(s): Royer et al.**

**Title: Methods for Producing Heterologous Polypeptides In  
Trichothecene-Deficient Filamentous Fungal Mutant Cells**

74 pages of specification 16 sheets of formal drawings

8 pages of Sequence Listing 3 sheets of Declaration and Power of Attorney

**[x] The filing fee is calculated as follows:**

Basic Fee:	\$710.00
Total Claims: $0 - 20 = 0 \times 18 =$	\$0
Independent Claims: $0 - 3 = 0 \times 80 =$	\$0
Total Fee:	\$710.00

This application is a divisional of U.S. application Serial No. **09/316,080** filed on **May 20, 1999** and claims priority from U.S. application Serial No. **09/082,217**, filed on **May 20, 1998**, now abandoned, which applications are fully incorporated herein by reference.

Address all future communications to Robert L. Starnes, Novo Nordisk Biotech, Inc., 1445 Drew Avenue, Davis, CA 95616.

09/710760-111000

[illegible]

Respectfully submitted,  
Nobut L. Hame

Robert L. Starnes, Reg. No. 41,324  
Novo Nordisk Biotech, Inc.  
1445 Drew Avenue  
Davis, CA 95616  
(530) 757-8100

## PATENT

Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

Re: U.S. Patent Application for  
"Methods For Producing Heterologous Polypeptides In  
Trichothecene-Deficient Filamentous Fungal Mutant Cells"  
Applicants: Royer *et al.*

Express Mail Label No.: EL285641612US

Date of Deposit: November 10, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Copy of Executed Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. Request Transfer of Computer Readable Sequence Listing
6. Verified Statement
7. Information Disclosure Statement
8. PTO-1449
9. 16 Sheets of Drawings

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

(Name of person mailing papers or fees)

Selste A. Buriani

(Signature of person mailing papers or fees)

**Mailing Address:**  
Novo Nordisk Biotech, Inc.  
1445 Drew Avenue  
Davis, CA 95616  
(530) 757-8100